Last reviewed · How we verify
NCT07358741
Standard Two-Day Advanced Life Support (ALS) Versus One Day Recertification Course
trial in Skill Performance in 158 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | National Hepatology & Tropical Medicine Research Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 158 |
| Start date | 12 December 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across Egypt |
Conditions studied
- Skill Performance — all drugs for Skill Performance →
- Knowledge — all drugs for Knowledge →
Sponsor
National Hepatology & Tropical Medicine Research Institute
Who can join
18 and older, any sex, with Skill Performance or Knowledge. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this study aims to compare the effectiveness of a one-day versus two-day ALS recertification course in terms of knowledge retention, practical skills performance, participant satisfaction, and confidence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07358741
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Hepatology & Tropical Medicine Research Institute trials
Trials by the same sponsor.
- NCT07085832 — Assessment of Cardiopumonary Resuscitation (CPR) Competency Post ALS Course · NA · recruiting
- NCT06063993 — Evaluation of Perfusion Index Change Post Passive Leg Raising for Fluid Responsiveness in Critically Ill · completed
- NCT04750135 — Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis · Phase 2 · unknown
- NCT04468685 — Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy · Phase 2 · completed
- NCT03455322 — Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07358741 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Hepatology & Tropical Medicine Research Institute
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07358741.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing